The FDA's psychedelic sea-change: what accelerated clinical trials for psilocybin, methylone, and ibogaine mean for mental health and neuroscience research | Boris Heifets
About this episode
The episode discusses the FDA's new approach to psychedelic medicine and its implications for mental health and neuroscience research.
Last month we saw a big shift in the federal government’s approach to psychedelic medicine. Specifically, following an executive order by President Trump, the FDA announced it is fast-tracking its review of several clinical trials of psychedelic drugs for patients with mental health disorders. The executive order also directed more funds towards psychedelic research and a review of psychedelics’ status as highly restricted Schedule 1 substances. To help us understand what all this means...
More episodes of From Our Neurons to Yours
- Sugar on the Brain | Carolyn Bertozzi
- After Ozempic: the revolution in peptide science | Jonathan Long
- Transcranial magnetic stimulation and the future of psychiatry | Corey Keller
- How brain imaging is transforming mental health (finally) | Leanne Williams
- Is chronic fatigue a gut-brain reflex? (Big Ideas in Neuroscience) | Julia Kaltschmidt
- Is neurodegeneration a waste-management problem? | Monther Abu-Remaileh
Explore listener stats, chart rankings, contacts and more on the From Our Neurons to Yours podcast page.